Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results

HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“HRGN” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced that it will release Q3 2023 financial results on November 13, 2023 and host a conference call and webcast on the same day November 13, 2023 at 9:00 AM ET to discuss financial results and business updates for the third-quarter 2023. There will be an opportunity for Q&A.

Conference Call & Webcast

Date: Monday, November 13, 2023
Time: 9:00 AM ET
Participant Dial-In: 877-407-8293 / [phone]

Participant Dial-In: 877-407-8293 / [phone]

Click here for participant International Toll-Free access numbers

Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=yVfbdcv ...

Call me: https://hd.choruscall.com/InComm/?callme=true&passcode=13728504&am ...

• Call me is a zero hold-time telephone dial-back service for participants.

Media - Telephone Replay: 877-660-6853 / 201-612-7415 Access ID: 13742676

Replay Duration: 1 week

About Harvard Apparatus Regenerative Technology

We are a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next-generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrifice of another of the patient’s own organs or permanent artificial implants.

We conducted the world’s first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. This surgery was performed by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. The procedure demonstrated that our technology was able to successfully regenerate esophageal tissue, including the mucosal lining, to restore the integrity, continuity and functionality of the esophageal tube.